Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Myelodysplastic Syndromes 21Leukemia, Myeloid, Acute 16Lymphoma 15Leukemia 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 13Lymphoma, Non-Hodgkin 13Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Follicular 12Hodgkin Disease 12Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, B-Cell, Marginal Zone 8Graft vs Host Disease 8Neoplasms, Plasma Cell 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myeloid, Accelerated Phase 7Congenital Abnormalities 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Burkitt Lymphoma 6Blast Crisis 6Waldenstrom Macroglobulinemia 5Primary Myelofibrosis 5Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Prolymphocytic 5Hematologic Neoplasms 5

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Tacrolimus × Clear all
NCT01871441 2025-05-16

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Thomas Jefferson University

Phase 2 Terminated
4 enrolled 10 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡